Joshua Chiappelli

Joshua Chiappelli

Auto-generated profile, based on publicly available information

Joshua Chiappelli

University of Maryland School of Medicine, Baltimore, USA

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2014 in JAMA Psychiatry
Verified
Journal Article
Open access
PDF file
JCJoshua Chiappelli
Joshua Chiappelli
APAna Pocivavsek
Ana Pocivavsek
KNKatie L. Nugent
Katie L. Nugent
FNFrancesca M. Notarangelo
Francesca M. Notarangelo
PKPeter Kochunov
Peter Kochunov
LHL. Elliot Hong
L. Elliot Hong
Converging lines of evidence implicate abnormalities in the kynurenine pathway (KP) of tryptophan degradation in schizophrenia.1-4 Increased concentrations of the KP metabolites kynurenine and kynurenic acid (KYNA) have been found in postmortem brain tissue1,2 and cerebrospinal fluid3,4 of individuals with schizophrenia. Moreover, genetic variants in KP enzymes have been linked to psychotic symptoms, cognitive dysfunctions, and abnormal levels of KYNA.5-7 In the brain, KYNA can act as an antagonist at N-methyl-d-aspartate and α7 nicotinic receptors, both of which have been closely associated with schizophrenia.8 At higher concentrations, KYNA can also be neuroprotective in conditions of excitotoxicity.9-11 However, the clinical significance of kynurenergic abnormalities in patients with schizophrenia remains unclear.

4 May 2016 in Neuropsychopharmacology
Verified
Journal Article
Closed access
PDF file
JCJoshua Chiappelli
Joshua Chiappelli
Teodor T. PostolacheTeodor T. Postolache
Teodor T. Postolache
PKPeter Kochunov
Peter Kochunov
LRLaura M Rowland
Laura M Rowland
SWS Andrea Wijtenburg
S Andrea Wijtenburg
LHL Elliot Hong
L Elliot Hong

27 February 2015 in Neuropsychopharmacology
Verified
Journal Article
Closed access
JCJoshua Chiappelli
Joshua Chiappelli
LRLaura M Rowland
Laura M Rowland
SWS Andrea Wijtenburg
S Andrea Wijtenburg
FMFlorian Muellerklein
Florian Muellerklein
MTMalle Tagamets
Malle Tagamets
LHL Elliot Hong
L Elliot Hong

18 July 2020 in Schizophrenia Bulletin
Verified
Journal Article
Open access
PDF file
PKPeter Kochunov
Peter Kochunov
AZArtemis Zavaliangos-Petropulu
Artemis Zavaliangos-Petropulu
NJNeda Jahanshad
Neda Jahanshad
PTPaul M Thompson
Paul M Thompson
MRMeghann C Ryan
Meghann C Ryan
LHL Elliot Hong
L Elliot Hong
Schizophrenia (SZ) is a severe psychiatric illness associated with an elevated risk for developing Alzheimer’s disease (AD). Both SZ and AD have white matter abnormalities and cognitive deficits as core disease features. We hypothesized that aging in SZ patients may be associated with the development of cerebral white matter deficit patterns similar to those observed in AD. We identified and replicated aging-related increases in the similarity between white matter deficit patterns in patients with SZ and AD. The white matter “regional vulnerability index” (RVI) for AD was significantly higher in SZ patients compared with healthy controls in both the independent discovery (Cohen’s d = 0.44, P = 1·10–5, N = 173 patients/230 control) and replication (Cohen’s d = 0.78, P = 9·10–7, N = 122 patients/64 controls) samples. The degree of overlap with the AD deficit pattern was significantly correlated with age in patients (r = .21 and .29, P < .01 in discovery and replication cohorts, respectively) but not in controls. Elevated RVI-AD was significantly associated with cognitive measures in both SZ and AD. Disease and cognitive specificities were also tested in patients with mild cognitive impairment and showed intermediate overlap. SZ and AD have diverse etiologies and clinical courses; our findings suggest that white matter deficits may represent a key intersecting point for these 2 otherwise distinct diseases. Identifying mechanisms underlying this white matter deficit pattern may yield preventative and treatment targets for cognitive deficits in both SZ and AD patients.

17 May 2013 in Schizophrenia Bulletin
Verified
Journal Article
Closed access
JCJoshua Chiappelli
Joshua Chiappelli
KNKatie L. Nugent
Katie L. Nugent
KTKavita Thangavelu
Kavita Thangavelu
KSKatherine Searcy
Katherine Searcy
LHL. Elliot Hong
L. Elliot Hong
Depression and negative symptoms can be difficult to distinguish in schizophrenia. Assessments for negative symptoms usually account for the longitudinal nature of these symptoms, whereas instruments available to measure depression mainly assess current or recent symptoms. This construct difference may confound comparison of depressive and negative symptoms in schizophrenia because both domains may have trait-like aspects. We developed an instrument to measure both longitudinal "trait" as well as recent "state" symptoms of depression and tested this instrument (Maryland Trait and State Depression [MTSD] scale) in a sample of 98 individuals with schizophrenia or schizoaffective disorder and 115 community participants without psychotic illness. Exploratory factor analysis of the MTSD revealed 2 factors accounting for 73.4% of the variance; these 2 factors corresponded with "trait" and "state" depression inventory items. Neither MTSD-state nor MTSD-trait was correlated with negative symptoms as measured with the Brief Negative Symptom Scale (r = .07 and -.06, respectively) in schizophrenia patients. MTSD state and trait scores were significantly correlated with the Brief Psychiatric Rating Scale depression subscale (r = .58 and .53, respectively) as well as the Profile of Mood States depression subscale (r = .57 and .44). Persons with schizophrenia had significantly greater trait depressive symptoms than controls (P = .031). Individuals with schizoaffective disorder had significantly higher trait depression (P = .001), but not state depression (P = .146), compared with schizophrenia patients. Trait depressive symptoms are prominent in schizophrenia and are distinct from negative symptoms.

1 March 2017 in Psychoneuroendocrinology
Verified
Journal Article
Closed access
JCJoshua Chiappelli
Joshua Chiappelli
PKPeter Kochunov
Peter Kochunov
ASAnya Savransky
Anya Savransky
FFFeven Fisseha
Feven Fisseha
KWKrista Wisner
Krista Wisner
LHL. Elliot Hong
L. Elliot Hong